ArticleFrontiers in medicine2025
Superior gastrointestinal visualization and safety of detachable string magnetically controlled capsule endoscopy in patients on antithrombotic agents.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Wireless magnetically controlled capsule endoscopy (WMCCE) offers a non-invasive alternative for patients on antithrombotic therapy, but it has limitations in esophageal visualization and carries risks of capsule retention. We aim to explore the safety and feasibility of detachable string magnetically controlled capsule endoscopy (ds-MCE) for patients on antithrombotic agents. Methods: This single-center, retrospective study included 387 patients on antithrombotic therapy who underwent magnetically controlled capsule endoscopy between October 2023 and October 2024: 86 with ds-MCE and 301 with WMCCE. Differences in the visualization of the esophagus and stomach, lesions detection and examination time of the esophagus, stomach and small intestine between the two groups were compared, and the safety of ds-MCE was assessed based on string-related discomfort and adverse events. The primary outcome was visualization of the oesophagus. The key secondary outcome was the safety of ds-MCE. Results: The ds-MCE group achieved significantly higher rates of complete visualization of the esophageal Z-line (52.3% vs. 6.3%, Conclusion: The ds-MCE improved esophageal visualization and lesion detection compared to WMCCE, offering a safer and less invasive alternative to esophagogastroduodenoscopy for patients on antithrombotic agents with excellent safety and tolerability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.